XML 114 R76.htm IDEA: XBRL DOCUMENT v3.8.0.1
Investments in Variable Interest Entities (Details) - USD ($)
$ in Millions
1 Months Ended
Oct. 31, 2017
Mar. 31, 2018
Dec. 31, 2017
Investment in Variable Interest Entities (Textual)      
Investment in biotechnology companies that are determined to be unconsolidated variable interest entities   $ 28.5 $ 48.3
Neurimmune      
Variable Interest Entity [Line Items]      
Payments to Neurimmune $ 150.0    
Reduction in royalty rate payable on commercial sales 15.00%    
Additional reduction in royalty rate payable on commercial sales 5.00%    
Additional Potential Payments to Noncontrolling Interest $ 50.0